FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107895289> ?p ?o ?g. }

• W2107895289 endingPage "21" @default.
• W2107895289 startingPage "3712" @default.
• W2107895289 abstract "Pretarget radioimmunotherapy (RIT) is a multistep strategy for cancer therapy designed to reduce nontarget organ exposure by uncoupling the tumor targeting moiety from the radioactive ligand. Using this approach, we and others have demonstrated objective responses to therapy among patients with non-Hodgkin's lymphoma, with less hematological toxicity than is typically seen at equivalent doses of conventional RIT in the same patient population. In the present study, we show that combination therapy with gemcitabine (200 mg/kg on days -1 and +1) and Pretarget RIT (400 micro Ci (90)Y-labeled DOTA-biotin on day +1) is superior to Pretarget monotherapy (400 or 800 micro Ci (90)Y) as well as to gemcitabine monotherapy in nude mice bearing established human LS174T colon cancer xenografts. For the targeting moiety, we used a murine anti-TAG-72 (CC49) single-chain Fv-streptavidin (scFvSA) fusion protein that has been shown to be safe and well-tolerated in humans. The median number of days to tumor volume doubling in the gemcitabine-only studies (200 mg/kg) was 10.4 +/- 5.5 days; in the Pretarget 400 micro Ci dose-only studies, tumor doubling time was 6.7 +/- 4.9 days; and in combination therapy studies, it was 23.9 +/- 7.2 days (P </= 0.0001 versus Pretarget or gemcitabine monotherapy). There were no consistently significant differences among the two monotherapy regimens and the combination therapy regimen with respect to peripheral blood cell counts, nor were there significant differences in bone marrow colony-forming activity among the three treatment groups. These data indicate that gemcitabine can be combined with Pretarget RIT to increase antitumor response, without increasing hematological toxicity, in a murine xenograft model." @default.
• W2107895289 created "2016-06-24" @default.
• W2107895289 creator A5000747443 @default.
• W2107895289 creator A5004714976 @default.
• W2107895289 creator A5022960930 @default.
• W2107895289 creator A5032586985 @default.
• W2107895289 creator A5048985521 @default.
• W2107895289 creator A5053467199 @default.
• W2107895289 creator A5057322511 @default.
• W2107895289 creator A5063667737 @default.
• W2107895289 creator A5076111835 @default.
• W2107895289 creator A5080904797 @default.
• W2107895289 creator A5087698813 @default.
• W2107895289 date "2003-09-01" @default.
• W2107895289 modified "2023-10-14" @default.
• W2107895289 title "Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy." @default.
• W2107895289 cites W1233276 @default.
• W2107895289 cites W1490430881 @default.
• W2107895289 cites W16661828 @default.
• W2107895289 cites W1835375318 @default.
• W2107895289 cites W1858303686 @default.
• W2107895289 cites W1914991379 @default.
• W2107895289 cites W1931508686 @default.
• W2107895289 cites W1972666371 @default.
• W2107895289 cites W1996785737 @default.
• W2107895289 cites W2004224153 @default.
• W2107895289 cites W2005404560 @default.
• W2107895289 cites W2007734777 @default.
• W2107895289 cites W2012189403 @default.
• W2107895289 cites W2013051417 @default.
• W2107895289 cites W2021007834 @default.
• W2107895289 cites W2021070333 @default.
• W2107895289 cites W2029318296 @default.
• W2107895289 cites W2031326397 @default.
• W2107895289 cites W2064405518 @default.
• W2107895289 cites W2083513265 @default.
• W2107895289 cites W2084406336 @default.
• W2107895289 cites W2103144075 @default.
• W2107895289 cites W2112397375 @default.
• W2107895289 cites W2119940209 @default.
• W2107895289 cites W2125775092 @default.
• W2107895289 cites W2142526477 @default.
• W2107895289 cites W2144599319 @default.
• W2107895289 cites W2154236718 @default.
• W2107895289 cites W2165573190 @default.
• W2107895289 cites W2411999269 @default.
• W2107895289 cites W2414599709 @default.
• W2107895289 cites W2489364296 @default.
• W2107895289 cites W2615655254 @default.
• W2107895289 cites W94590171 @default.
• W2107895289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14506163" @default.
• W2107895289 hasPublicationYear "2003" @default.
• W2107895289 type Work @default.
• W2107895289 sameAs 2107895289 @default.
• W2107895289 citedByCount "13" @default.
• W2107895289 countsByYear W21078952892012 @default.
• W2107895289 countsByYear W21078952892013 @default.
• W2107895289 countsByYear W21078952892016 @default.
• W2107895289 countsByYear W21078952892018 @default.
• W2107895289 countsByYear W21078952892019 @default.
• W2107895289 crossrefType "journal-article" @default.
• W2107895289 hasAuthorship W2107895289A5000747443 @default.
• W2107895289 hasAuthorship W2107895289A5004714976 @default.
• W2107895289 hasAuthorship W2107895289A5022960930 @default.
• W2107895289 hasAuthorship W2107895289A5032586985 @default.
• W2107895289 hasAuthorship W2107895289A5048985521 @default.
• W2107895289 hasAuthorship W2107895289A5053467199 @default.
• W2107895289 hasAuthorship W2107895289A5057322511 @default.
• W2107895289 hasAuthorship W2107895289A5063667737 @default.
• W2107895289 hasAuthorship W2107895289A5076111835 @default.
• W2107895289 hasAuthorship W2107895289A5080904797 @default.
• W2107895289 hasAuthorship W2107895289A5087698813 @default.
• W2107895289 hasConcept C121608353 @default.
• W2107895289 hasConcept C126322002 @default.
• W2107895289 hasConcept C143998085 @default.
• W2107895289 hasConcept C1491633281 @default.
• W2107895289 hasConcept C159654299 @default.
• W2107895289 hasConcept C203014093 @default.
• W2107895289 hasConcept C2776146153 @default.
• W2107895289 hasConcept C2776999253 @default.
• W2107895289 hasConcept C2780258809 @default.
• W2107895289 hasConcept C2781413609 @default.
• W2107895289 hasConcept C2908647359 @default.
• W2107895289 hasConcept C48900799 @default.
• W2107895289 hasConcept C526805850 @default.
• W2107895289 hasConcept C542903549 @default.
• W2107895289 hasConcept C54355233 @default.
• W2107895289 hasConcept C71924100 @default.
• W2107895289 hasConcept C86803240 @default.
• W2107895289 hasConcept C90924648 @default.
• W2107895289 hasConcept C98274493 @default.
• W2107895289 hasConcept C99454951 @default.
• W2107895289 hasConceptScore W2107895289C121608353 @default.
• W2107895289 hasConceptScore W2107895289C126322002 @default.
• W2107895289 hasConceptScore W2107895289C143998085 @default.
• W2107895289 hasConceptScore W2107895289C1491633281 @default.
• W2107895289 hasConceptScore W2107895289C159654299 @default.
• W2107895289 hasConceptScore W2107895289C203014093 @default.

• next